{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'As much as possible, subjects should be seen for all scheduled visits on the designated day.', 'There is a +5 day visit window for all study visits with the exception of the 3 Safety', 'Follow-Up Visits (7 days).', 'If a subject misses a visit and comes for an Unscheduled Visit, procedures for the assessment', 'of safety and efficacy should be performed according to the most recent visit that was', 'omitted. When a protocol-required procedure cannot be performed, the Investigator will', 'document in the source documents the reason for this and any corrective and preventive', 'actions that he/she has taken to ensure that normal processes are adhered to as soon as', 'possible. The study team should be informed of these incidents in a timely fashion.', 'The assessments to be performed at each study visit should be conducted in the standard', 'order listed below. At all visits, the PRO questionnaires should be performed first, prior to', 'any discussion between the subject and study site staff.', 'The standard order should be:', 'All PRO questionnaires (prior to any discussion between the subject and study site', 'staff)', '- Patient Global Assessment of Disease Activity (Visual Analog Scale [VAS])', '- Patient Assessment of Pain (VAS)', '- HAQ-DI', '- SF-36', '- EQ-5D', '- FACIT-Fatigue', '- WPS-RA (this PRO is conducted by study site staff after the subject completes all', 'other PROs)', 'Joint counts (Independent Joint Assessment)', 'Soliciting of AE information', 'Physician Global Assessment (VAS)', 'All other assessments', 'In the following sections, assessments are listed for each visit according to this order.', 'Amendment 2: 06 March 2019', '57', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '5.4.1', 'Open-label Treatment Period Visits: Visit 1 (OLE Baseline/Week 24)', 'through Visit 9 (Week 88)', '5.4.1.1', 'Visit 1 (OLE Baseline/Week 24)', 'Written informed consent for the OLE study must be obtained prior to the performance of', 'any protocol-specific procedures at Visit 1 (OLE Baseline/Week 24). The Investigator at', 'each study site will ensure that each subject has been provided with full and adequate oral', 'and written information about the nature, purpose, and available details of possible risks and', 'benefits of the study.', 'Subjects must also be notified that they are free to discontinue from the study treatment or', 'the whole study at any time. The Investigator will discuss with the subject the importance of', 'attending all scheduled study site visits, including the EoT Visit and Safety Follow-Up', 'Visits, regardless of whether the subject chooses to discontinue from the study treatment, or', 'not. The subject should be given the opportunity to ask questions and allowed adequate time', 'to consider the written information provided. The Investigator must retain the original,', 'signed informed consent form (ICF) for the study file. A copy of the signed ICF must be', \"given to the subject. Once informed consent has been obtained, the subject's eligibility to\", 'enter the study will be verified in accordance with the inclusion and exclusion criteria (refer', 'to Sections 5.3.1 and 5.3.2, respectively).', 'If a subject meets all study eligibility criteria, the Investigator will randomize the subject via', 'the Interactive Web Response System (IWRS) to one of the two open-label treatment groups', '(see Section 5.2). Subjects will keep the same subject number that they were assigned during', 'the core study.', 'Visit 1 (OLE Baseline/Week 24) in the OLE study is the same as the Visit 15 (EoT/Week 24)', 'visit in the core CREDO studies. Any assessments specified for the OLE Baseline Visit that', 'duplicate the assessments specified for Week 24 in the core studies should only be performed', 'once.', 'In addition to obtaining subject informed consent, the following assessments should be', 'performed:', 'Check eligibility criteria.', 'Randomize subject (Via IWRS)', 'Administer Patient Global Assessment of Disease Activity (VAS) (see Section 7.1.3).', 'Administer Patient Assessment of Pain (VAS) (see Section 7.1.4).', 'Administer HAQ-DI (see Section 7.1.10.1).', 'Amendment 2: 06 March 2019', '58', 'Confidential']\n\n###\n\n", "completion": "END"}